Istvan Redei is a Hematology physician. OpenAlex indexes 23 publications with 647 citations (h-index 12).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- JanssenProgram year20231 paymentResearch
- Celgene CorporationProgram year20233 payments
- BeiGene USA, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
38.5%Thalidomide Analog17.5%Revlimid41%Pomalyst34%Lenalidomide25%Part D<11 patientsKinase inhibitor12.1%Calquence60%Imbruvica41%Part D<11 patients+ 2 more classes in this area
Dermatology
33.6%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor33.6%Acyclovir100%Part D≥40 patientsMetabolism & gastrointestinal
12.4%Potassium supplement5.2%Potassium Chloride100%Part D<11 patientsCorticosteroid3.7%Prednisone100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- with increased relapse after allogeneic2016
- Brief report Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation2016
- Hematopoietic Cell Transplantation with Cord Blood for Cure of HIV Infections
Transplantation and Cellular Therapy
2012 - Cord Blood Transplantation for Long Term Management or Possible Cure of HIV Infection
Transplantation and Cellular Therapy
2012
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Joseph Antin, MD
Harvard University
Scott Kaufmann, MD
Mayo Clinic College of Medicine
Ruben Mesa, MD
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Jaroslaw Maciejewski, MD
Cleveland Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”